glp-1 for mash BREAKTHROUGH: FDA APPROVES TREATMENT SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Exploring the Potential of GLP-1

This might be because the limited time of LOsG treatment resulted in a conversion of a subset of -cells to -cells at early stage, and others had not started to change yet

.

However, the mechanistic rationale for combining these agents is sound and warrants further investigation

Shared side effects both medications can cause: Nausea (most common, especially when starting) Vomiting Diarrhea or constipation Stomach discomfort Loss of appetite Headache Dizziness Semaglutide-specific notes: Side effects are generally mild to moderate, and they often decrease as your body adjusts over the first few weeks

transfer to -20 C or below on arrival